Monthly Archives: February 2012

For anyone wondering about the value that can be added by entrepreneurs and venture capitalists to the drug discovery and development process, look no further than Stromedix, acquired on Feb. 14, 2012 by Biogen Idec for up to $562 million ($75 million up-front). The kicker: Stromedix acquired STX-100, its primary asset, from Biogen Idec in 2007 for well under $5 million. Talk about added value. Continue reading →